Effects of transdermal 17β-estradiol on left ventricular anatomy and performance in hypertensive women

Hypertension

Volumn 34, Issue 5, 1999, Pages 1041-1046

  Modena, Maria Grazia ^a   Muia Jr , Nicola ^b   Aveta, Pietro ^b   Molinari, Rosella ^b   Rossi, Rosario ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b NONE

Author keywords

Drugs; Echocardiography; Estrogen; Hypertension, mild; Hypertrophy; Menopause; Trials

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRADIOL; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE PERFORMANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSDERMAL DRUG ADMINISTRATION; DRUG EFFECT; ESTROGEN THERAPY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED;

ADMINISTRATION, CUTANEOUS; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; POSTMENOPAUSE; VENTRICULAR FUNCTION, LEFT;

EID: 0032589967     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.34.5.1041     Document Type: Article

References (38)

1. Grossman W, Jones D, McLaurin LP. Wall Stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56:56-65.
2. Kannel WB, Sorlie P. Left ventricular hypertrophy in hypertension: prognostic and pathogenetic implication: the Framingham Study. In: Strauer BNE. ed. The Heart in Hypertension. Berlin, Germany: Springer-Verlag: 1981;223-242.
3. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implication of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
4. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA. 1995;273:199-208.
5. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Etlinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
6. Foison AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health. 1995;85: 1128-1132.
7. Grodstain F, Stampfer MJ, Colditz GA, Willet WC, Manson JAE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1769-1775.
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart, and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-611.
9. Crook D, Cust MP, Gangar KF, Worthington M, Hillard TC, Stevenson JC, Whitehead MI, Wynn V. Comparison of transdermal and oral estrogen/progestin replacement therapy: effect on serum lipids and lipoprotein. Am J Obstet Gynecol. 1992;166:950-955.
10. Stevenson JC, Crook D, Godsland IF, Lees B, Whitehead MD. Oral versus transdermal hormonal replacement therapy. Int J Fertil Menopausal Stud. 1993;38:30-35.
11. Modena MG, Rossi R, Muia N Jr, Origliani G, Rombola O, Molinari R. Short-term results of transdermal estrogen replacement therapy in cardiovascular disease-free postmenopausal females with and without hypertension. G Ital Cardiol. 1998;28:636-644.
12. Giraud G, Morton MJ, Davis LE, Paul MS, Thornburg KL. Estrogen-induced left ventricular chamber enlargement in ewes. Am J Physiol. 1993;264:E490-E496.
13. The Fifth Report of the Joint National Committee on Detection. Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-291.
14. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens. 1992;5:207-209.
15. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
16. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight J Am Coll Cardiol. 1992;20:1251-1260.
17. Ganau A, Devereux RB. Roman MJ, deSimone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
18. de Divitiis O, Celentano A, de Simone G, Di Somma S, Galderisi M, Liguori V, de Divitiis M, Petitto M. Management of the patients with left ventricular hypertrophy. Eur Mean J. 1993;14:D22-D32.
19. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
20. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by different types of antihypertensive therapy. J Hum Hypertens. 1992;6:85-90.
21. Fouad FM, Slominski JM, Tarazy RC. Left ventricular diastolic function in hypertension: relation to left ventricular mass and systolic function. J Am Coll Cardiol. 1984;3:1500-1508.
22. Strauer BE. Significance of coronary circulation in hypertensive heart disease for development and prevention of heart failure. Am J Cardiol. 1990;65:G34-G41.
23. Grassi G, Gianattasio C, Cleroux J, Cuspidi C, Sampieri L, Mancia G. Cardiopulmonary reflex before and after regression of left ventricular hypertrophy in essential hypertension. Hypertension. 1988;12:227-231.
24. Ayobe Mh, Tarazi RC. β-Receptors and contractility reserve in left ventricular hypertrophy. Hypertension. 1983;5:1192-1197.
25. Gonzales-Femandes RA, Rivera M. Rondriguez PJ, Fernandez-Martinez J, Soltero L, Diaz L, Lugo J. Prevalence of ectopic ventricular activity after left ventricular mass regression. Am J Hypertens. 1993;6:308-313.
26. Levy D, Salomon M, D'Agostino R, Belanger A, Kannel WB. Prognostic implication of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994: 90:1786-1793.
27. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995;13:1091-1095.
28. Yurenev AP, Dyakotonova HG, Novikov ID, Vitols A, Pahl L, Haynemann G. Management of essential hypertension in patients with different degrees of left ventricular hypertrophy: a multicenler trial. Am J Hypertens. 1992;5(pt 2):S182-S189.
29. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Reboldi G. Porcellaii C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998;97:48-54.
30. Schmieder RE, Messerli FH, Sturgill D, Garavaglia GE, Nunez BD. Cardiac performance after reduction of myocardial hypertrophy. Am J Med. 1989;87:22-27.
31. Muiesan ML, Agabiti-Rosei E, Romanelli G, Beschi M, Castellano M, Alari G, Rizzoni D, Muiesan G. Improved left ventricular systolic and diastolic function after regression of cardiac hypertrophy, treatment withdrawal and redevelopment of hypertension. J Cardiovasc Pharmacol. 1991;17:179S-18IS.
32. deSimone G, Devereux RB, Roman MJ, Ganau A, Saba PS, Aiderman MH, Laragh JH. Assessment of left ventricular function by midwall fractional shortening end-systolic stress relation in human hypertension. J Am Coll Cordial. 1994;23:1444-1451.
33. 2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol. 1992;106:739-745.
34. 2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol. 1994;266:C975-C980.
35. Schunkert H, Danser AHJ, Hense HW, Derkx FHM, Kurzinger S, Riegger GAJ. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation. 1997;95: 39-45.
36. Proudler AJ, Ahmcd AIH, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-convertingenzyme activity in postmenopausal women. Lancet. 1995;346:89-90.
37. Cheng DY, Gruetter CA. Chronic estrogen alters contractile responsiveness to angiotensin II and norepinephrine in female rat aorta. Eur J Pharmacol. 1992;215:171-176.
38. Mercuro G, Zoncu S, Pilia I, Lao A, Melis GB, Cherchi A. Effects of acute administration of transdermal estrogen on postmenopausal women with systemic hypertension. Am J Cardiol. 1997;80:652-655.